Hot Small Cap Stocks For 2015

Hot Small Cap Stocks For 2015: Achillion Pharmaceuticals Inc.(ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic HCV include ACH-1625, a protease inhibitor, which is in phase IIa clinical trial for the treatment of chronic HCV; ACH-2684, a pangenotypic protease inhibitor, which is in phase I clinical trial for the treatment of chronic HCV infection; and NS5A inhibitors for the treatment of chronic HCV infection, including ACH-2928, which is to enter a phase I clinical trial, as well as various additional NS5A inhibitors in preclinical development. Its pipeline of product candidates also includes ACH-702 and ACH-2881 for drug resistant bacterial infections; elvucitabine for HIV infection; and AC H-1095 for HCV infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Advisors' Opinion:

• [By Ben Levisohn]

  Achillion Pharmaceuticals (ACHN) has plunged 51% to $3.53 after the FDA kept a hold on its hepatitis C drug in trials. The stock was downgraded to Underperform from Neutral at Merrill Lynch.

• [By Sean Williams]

  In terms of clinical updates, hepatitis-C-focused biotech Achillion Pharmaceuticals (NASDAQ: ACHN  ) announced updated midstage results for its lead compound, ACH-3102, on Tuesday. In trials of genotype-1b treatment naive patients, ACH-3102 plus a ribavirin delivered a 75% success rate in end-of-treatment virologic response. The problem with these results is that not only is Achillion far behind its all-oral peers in terms of development, but its 75% success rate trailed that of Gilead Sciences' Sofosbuvir, which delivered 100% success rates in ! some of its late-stage trials featuring genotype-1 patients.

• [By Jon C. Ogg]

  Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) is getting destroyed on poor hep-C test results, and shares are down about 50%. Bank of AmericaMerrill Lynch downgraded it to Underperform from Buy after the news.

• [By Grace L. Williams]

  We took a look at Achillion Pharmaceuticals (ACHN) after two directors bought 40,000 shares for $394,800. Dennis Liotta bought 20,000 shares for $158,100 and Jason Fisherman bought 20,000 shares for $155,000. InsiderScore gave Liotta a nod, writing, Liotta has been a smart buyer at Achillion in the past. He bought the same number of shares here, this time at a price 28% higher, which is the highest price he has paid for shares.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/hot-small-cap-stocks-for-2015.html